New Posts New Posts RSS Feed - Expression Based Patient Stratification For TNBC
  FAQ FAQ  Forum Search   Events   Register Register  Login Login

Expression Based Patient Stratification For TNBC

 Post Reply Post Reply
Author
trip2 View Drop Down
Senior Member
Senior Member
Avatar

Joined: Jun 03 2007
Location: Under Palm Tree
Status: Offline
Points: 8549
Post Options Post Options   Thanks (0) Thanks(0)   Quote trip2 Quote  Post ReplyReply Direct Link To This Post Topic: Expression Based Patient Stratification For TNBC
    Posted: Mar 01 2010 at 6:19pm
February 26, 2010 - Friday 

Category: Life
 
NMSP
Novel Molecular Solution Protocols
T.Vicedomine
Cyto-Molecular Technologist
ASCP/CT/CME –ASIP JMD/CME
Path Molecular Department
 
INTRODUCTION
 
TNBC patients comprise a range of 15-30 % of the total population of Breast Cancer patients.
A simple test, dictates and identifies two separate oncological pathways that once identified, would greatly enhance the lives of over 200,000 women that are diagnosed TNBC on an annual basis. A more complex profile can be dictated by molecular assay, re-affirming the presence of known expressive reoccurring pathways.
Also  treating the patients which have presence of the retinoblastoma protein , early on with blockers such as HSP 90 (PU-H71), Parp1 inhibitors and Gem/Carbo compounds, while we cannot change the clinical outcome for this group at this time, we can significantly suppress, thus extending  the longevity from >4 months, once re-occurrence has been shown , to far  greater lengths.  Additional research is being done to shut down the activation of this pathway with the EF2 protein.
We’re treating TNBC patients, in the secondary pathway too late. We’re been treating TNBC patients with  traditional modalities, and this can change for the better with Pathology assisting these patients in identifying which way their disease is headed, not at the end game, but at the beginning.
( At least five journals site this.) 
It has also been established that these CTC’s or TICS. (Circulating Tumor Cells) (Tumor Initiating Cells)  (Tumor stem cells) exist well before (at the onset) the tumor manifest itself into a re-occurrence.
The second pathway is one which expressed the retinoblastoma gene (found on chromosome 13) in a hyper- metholated or normal state, and causes a ripple effect of the cascading over expressions and pathways we now know that TNBC patients exhibit.
The disease of TNBC takes two distinct pathways. It has been shown through documented scientific research that if a TNBC patient shows a loss of the retinoblastoma protein, and is treated with CMF followed by a low dose tamoxifen follow up, the survival rate is at 100%. This has been documented for more than a significant number of patients and in at least three scientific journals. It represents approximately 40 % of the overall population of TNBC patients.
TNBC patients have variable prognostic outcomes. Some survive this cancer, some don’t. Recurrence is high and clinical outcomes upon reoccurrence are very poor.
From this I have drawn the following conclusion which are based upon documented science, and revisited research by more than one group. All journals are available in my office should you wish to cross-check my conclusions.
I have researched 522 abstracts, and fully investigated approximately 50 full journal articles on TNBC.
Stage 2 2003
Stage 1 2007
BRCA 1+
Back to Top
 Post Reply Post Reply
  Share Topic   

Forum Jump Forum Permissions View Drop Down

Forum Software by Web Wiz Forums® version 12.01
Copyright ©2001-2018 Web Wiz Ltd.